

Akums launches novel Combikit for treatment of Duodenal Ulcer and H. pylori infection

26 April 2023 | News

In India, there are a large number of patients that suffer from duodenal ulcer and H pylori infection

New Delhi-based Akums Drugs and Pharmaceutical has announced the launch of its latest formulation, a unique Combikit – (Amoxicillin + Clarithromycin + Esomeprazole). This Combikit is the first of its kind to be introduced in India by Akums.

Combikit (Amoxicillin + Clarithromycin + Esomeprazole) is approved by the Central Drugs Standard Control Organisation (CDSCO) for the healing of duodenal ulcers associated with Helicobacter pylori (H. pylori) and eradication of H. pylori in patients with active or healed peptic ulcer.

The H. pylori eradication therapy has shown efficacy in reducing the risk of ulcer recurrence, providing a great benefit for patients. H. pylori is a very common infection in India, implicated in the etiology of gastritis and peptic ulcers in humans.

This Combikit is a combination of three effective drugs - Amoxicillin, Clarithromycin, and Esomeprazole. This combination works by inhibiting the growth of H. pylori bacteria and reducing the production of gastric acid. The drug is available in a patient convenient pack, for a complete course of therapy.